Molecular spreading and predictive value of preclinical IgE response to Phleum pratense in children with hay fever

Hatzler, Laura; Panetta, Valentina; Lau, Susanne; Wagner, Petra; Bergmann, Renate L.; Illi, Sabina; Bergmann, Karl E.; Keil, Thomas; Hofmaier, Stephanie; Rohrbach, Alexander; Bauer, Carl Peter; Hoffman, Ute; Förster, Johannes; Zepp, Fred; Schuster, Antje; Wahn, Ulrich; Matricardi, Paolo Maria

doi:10.1016/j.jaci.2012.05.053

Cited by 238 publications

(279 citation statements)

References 32 publications

Supporting

Mentioning

245

Contrasting

Unclassified

Order By: Relevance

“…It increased in serum concentration and complexity through a "molecular spreading" process during the preclinical and clinical course. Thus, testing IgE sensitization may facilitate prediction of seasonal allergic rhinitis at its early molecular sensitization stage [36]. In contrast, in patients with established allergic asthma, the variability in serum total IgE may prevent it from being used as a marker of asthma severity, although a cut point of 400 IU/mL could be suggestive of more severe disease [37].…”

Section: Main Immunological Changes Induced By Aitmentioning

confidence: 99%

Specific allergen immunotherapy for the treatment of allergic asthma: a review of current evidence

Domínguez‐Ortega

Delgado

Blanco

et al. 2017

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

Asthma is frequently associated with atopy, characterized by the production of specific immunoglobulin E in response to environmental allergens. Currently, two types of allergen immunotherapy (AIT) are used in clinical practice: subcutaneous and sublingual immunotherapy, both accepted as key components of the therapeutic repertoire for allergic rhinitis and conjunctivitis. However, their role in asthma remains controversial. The present document is aimed at providing the clinicians with a review of the evidence on the use of AIT in asthma, focusing on the most relevant aspects of its mechanism of action, its efficacy, and existing data on safety, tolerability, and cost-effectivity, both in pediatric and adult populations. A systematic search of MEDLINE, Cochrane, and Clinical Trials databases from 2000 to April of 2016 was carried out by a panel of experts from the Spanish Allergy and Clinical Immunology Scientific Society. Relevant studies prior to the year 2000 included in ulterior systematic reviews were also considered. More than 4000 articles were identified during the search and 241 were selected to retrieve available evidence on AIT, which was graded according to the Oxford classification. All the group members reviewed the resulting text until the final version reached the consensual agreement. A summary of recommendations on the more relevant topics are proposed. The role of AIT as a valuable therapeutic strategy for prevention of exacerbation and progressive decline in lung function is highlighted. Future research should include specific tools for asthma evaluation when assessing AIT effectiveness in asthmatic patients. ResumenEl asma se asocia frecuentemente con alergia, entendida ésta como la producción de IgE específica frente a alérgenos ambientales. Actualmente, existen dos tipos de inmunoterapia específica con alérgenos (ITE) para la práctica clínica habitual: subcutánea y sublingual, ambas indicadas en el tratamiento de la rinitis y la conjuntivitis alérgicas. Sin embargo, su papel en el asma resulta todavía controvertido. Dominguez-Ortega J, et al.

show abstract

Section: Main Immunological Changes Induced By Aitmentioning

confidence: 99%

Specific allergen immunotherapy for the treatment of allergic asthma: a review of current evidence

Domínguez‐Ortega

Delgado

Blanco

et al. 2017

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

show abstract

“…MAS cohort study analyzed the main risk factors for persistent asthma/wheeze in an early adolescent's period. According to the results from this huge study wheezing before the age of 3 as well as wheezing after the age of 6, accompanied with early atopic dermatitis, positive family history of atopic diseases and positive allergy tests, particular to perennial allergens represent the main risk factors [4,5].…”

Section: Epidemiology Of Asthma and Rhinitismentioning

confidence: 97%

Current Issues on Immunotherapy in Children

Djuric-Filipovic¹,

Živanović²,

Kostić³

et al. 2017

Allergen

View full text Add to dashboard Cite

Therapy of allergic diseases in children implicates avoidance of allergens, standard pharmacotherapy, and immunotherapy. Immunotherapy is the only treatment for allergic diseases with the ability to change the natural course of the disease, thus stopping its further progression as well as the development of new allergic diseases and new sensibilizations. The objective of this chapter is to give insight into the latest data on immunotherapy in treating children with allergic diseases. Methods: The study involved a search for relevant articles on the MEDLINE and PubMed up to 2017. Results: Numerous studies have shown that the sublingual application of allergen-specific immunotherapy is adequate, safe, and efficient in the therapy of immunoglobulin E (IgE)-mediated allergic diseases of the respiratory tract in children, but there are still some questions to be solved concerning the usage of SLIT in children younger than 5 years old, SLIT for polysensitized patients, duration of SLIT, long-lasting effects of SLIT. Conclusions: In order to improve the clinical efficacy of SLIT, we are looking for new routes of administration, new allergens, new protocols as well as combination of SLIT with other immune modulatory treatments.

show abstract

“…It remains firm that molecular allergy diagnosis, especially with multiplexed instruments, remains a third-line approach, to be used only in patients with a complex polysensitization profile, and when the standard diagnostics are insufficient to choose the appropriate allergen(s) for AIT [12]. On the other hand, a "tailored" AIT, using only the genuine sensitizers seems difficult to realize, since there are too many different sensitization profiles [39][40][41], and so far, commercial extracts (that are less expensive) perform as well as purified/recombinant molecules for AIT [42,43]. Allergen specific immunotherapy (AIT) is a well-documented effective treatment for respiratory and hymenoptera venom allergy [44][45][46][47][48][49].…”

Section: Allergen Immunotherapy Molecular Based Diagnostics and Pmmentioning

confidence: 99%

Molecular diagnosis and precision medicine in allergy management

Riccio

Ferrari

Chiappori

et al. 2016

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Precision medicine (PM) can be defined as a structural model aimed at customizing healthcare, with medical decisions/products tailored on an individual patient at a highly detailed level. In this sense, allergy diagnostics based on molecular allergen components allows to accurately define the patient's IgE repertoire. The availability of highly specialized singleplexed and multiplexed platforms support allergists with an advanced diagnostic armamentarium. The therapeutic intervention, driven by the standard diagnostic approach, but further supported by these innovative tools may result, for instance, in a more appropriate prescription of allergen immunotherapy (AIT). Also, the phenotyping of patients, which may have relevant effects on the treatment strategy, could be take advantage by the molecular allergy diagnosis.

show abstract

Molecular spreading and predictive value of preclinical IgE response to Phleum pratense in children with hay fever

Cited by 238 publications

References 32 publications

Specific allergen immunotherapy for the treatment of allergic asthma: a review of current evidence

Specific allergen immunotherapy for the treatment of allergic asthma: a review of current evidence

Current Issues on Immunotherapy in Children

Molecular diagnosis and precision medicine in allergy management

Contact Info

Product

Resources

About